New Study: Abatacept Therapy Offers Promising Results Treating Juvenile Dermatomyositis
(Source: NIEHS - National Institute of Environmental Health Sciences - News)
Source: NIEHS - National Institute of Environmental Health Sciences - News - March 8, 2023 Category: Environmental Health Source Type: research
Transcriptomic profile comparison of monocytes from rheumatoid arthritis patients in treatment with methotrexate, anti-TNFa, abatacept or tocilizumab
by Maria Talmon, Marcella Percio, Joyce Afrakoma Obeng, Federico A. Ruffinatti, Daniele Sola, Pier Paolo Sainaghi, Emanuela Bellis, Stefano Cusinato, Aurora Ianniello, Luigia G. Fresu
It is well documented that patients affected by rheumatoid arthritis (RA) have distinct susceptibility to the different biologic DMARDs available on the market, probably because of the many facets of the disease. Monocytes are deeply involved in the pathogenesis of RA and we therefore evaluated an d compared the transcriptomic profile of monocytes isolated from patients on treatment with methotrexate alone or in combination with tocilizumab,...
Source: PLoS One - March 6, 2023 Category: Biomedical Science Authors: Maria Talmon Source Type: research
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
ConclusionsThe stringent primary endpoint was not met. However, in patients achieving sustained SDAI remission, numerically more maintained remission with continued abatacept + methotrexate versus abatacept monotherapy or withdrawal.Trial RegistrationClinicalTrials.gov identifier, NCT02504268.Video abstract (MP4 62241 KB) (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 3, 2023 Category: Rheumatology Source Type: research
Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN ‐101) Reveals Non‐Redundant Roles of T Cell Co‐Stimulation Pathways in Inflammatory Arthritis
ConclusionBoth CD28 and ICOS signaling play critical roles in inflammatory arthritis. Therapeutic agents such as acazicolcept that co-inhibit both ICOS and CD28 signaling may mitigate inflammation and/or disease progression in RA and PsA more effectively than inhibitors of either pathway alone.This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - March 2, 2023 Category: Rheumatology Authors: Stacey R. Dillon,
Lawrence S. Evans,
Katherine E. Lewis,
Susan Debrot,
Tiffany C. Blair,
Sherri Mudri,
Kayla Kleist,
Steven D. Levin,
Janhavi G. Bhandari,
Logan Garrett,
Martin F. Wolfson,
Pamela M. Holland,
Mark W. Rixon,
Stanford L. Peng Tags: Full Length Source Type: research
Serum cytokines and bone metabolic markers in patients with rheumatoid arthritis treated with biological disease modifying anti-rheumatic drugs
ConclusionsbDMARDs with different modes of action exert different effects on the cytokine and bone metabolic marker levels in patients with RA.Key Points• While clinical effectiveness is comparable with infliximab, tocilizumab, and abatacept in patients with rheumatoid arthritis, changes in cytokine and bone metabolic marker levels are distinct among bDMARDs.• Especially, changes in interferon-γ, tumor necrosis factor-α levels with infliximab, interleukin-6, bone-specific alkaline phosphatase, osteocalcin levels with tocilizumab, and interleukin-1β, interleukin-8 levels with abatacept are significant. (Source: Clinical Rheumatology)
Source: Clinical Rheumatology - February 18, 2023 Category: Rheumatology Source Type: research
Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing
CONCLUSIONS: We identified new shared risk loci with functional impact in vasculitis and pinpointed potential causal genes, some of which could represent promising targets for the treatment of vasculitis.PMID:36797040 | DOI:10.1136/ard-2022-223697 (Source: Atherosclerosis)
Source: Atherosclerosis - February 16, 2023 Category: Cardiology Authors: Lourdes Ortiz-Fern ández Elio G Carmona Martin Kerick Paul Lyons Francisco David Carmona Raquel L ópez Mejías Chiea Chuen Khor Peter C Grayson Enrico Tombetti Lindi Jiang Haner Direskeneli Guher Saruhan-Direskeneli Jos é-Luis Callejas-Rubio Augusto Va Source Type: research
Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial
We read with interest the article by Felten et al which assessed the efficacy of interleukin 6 receptor inhibition (tocilizumab) in Sjögren’s syndrome (SjS).1 SjS is a chronic rheumatic disease characterised by immune infiltrates into exocrine glands such as salivary and lacrimal glands, which can impair glandular function and result in profound dryness.2 Despite the substantially expanded knowledge on its pathogenesis, the management of SjS has not been improved substantially in recent decades, and there are still some unmet needs in both the diagnosis and management of SjS.3 4 Currently available therapies ...
Source: Annals of the Rheumatic Diseases - February 10, 2023 Category: Rheumatology Authors: Wang, B., Chen, S., Xuan, J., Li, Y., Zheng, Q., Zhang, X., Liu, Y., Shi, G. Tags: ARD Correspondence Source Type: research
Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial by Wang et al
We read with interest the correspondence related to our article, ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial’, by Wang et al1 who discuss the disappointing results of recent trials of primary Sjögren syndrome (pSS). To explain recent negative results of tocilizumab and abatacept, apart from the inefficacy of these biologicals in pSS, Wang et al discuss the contribution of the design of the study. First, they discuss the choice of a primary endpoint based on the EULAR Sjögren’s Syndrome Disease Activi...
Source: Annals of the Rheumatic Diseases - February 10, 2023 Category: Rheumatology Authors: Felten, R., Gottenberg, J.-E. Tags: ARD Correspondence response Source Type: research
Risk of hepatitis B reactivation in HBsAg −/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta‐analysis
ConclusionsThis meta-analysis demonstrates the highest potential risk of HBV reactivation in HBsAg −/HBcAb+ RA patients receiving RTX treatment, especially HBsAb− patients. Our study furthers the understanding of the prophylactic use of anti-HBV drugs in such patients. However, it is relative safety to use the inhibitors of IL-6, TNF-α, and JAK in these patients. (Source: Immunity, Inflammation and Disease)
Source: Immunity, Inflammation and Disease - February 9, 2023 Category: Allergy & Immunology Authors: Xuezhi Hong,
Yanhua Xiao,
Liyan Xu,
Lei Liu,
Hailu Mo,
Hanyou Mo Tags: REVIEW ARTICLE Source Type: research
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
ConclusionsIn adjusted analyses, CCP+ patients with RA initiating treatment with abatacept versus tofacitinib did not show a statistically significant difference in reducing disease activity or improving patient-reported outcomes. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 7, 2023 Category: Rheumatology Source Type: research
[TRANSLATED ARTICLE] Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases
CONCLUSIONS: In this context of chronic treatments with teratogenic potential, it is necessary to highlight the importance of pregnancy planning to select the safest drug. Given the quality of the available data, it is still necessary to continuously update the information, as well as to promote observational studies of cohorts of pregnant patients and men of childbearing age, including prospective studies, in order to generate more scientific evidence.PMID:36732114 | DOI:10.1016/j.farma.2022.12.016 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - February 2, 2023 Category: Drugs & Pharmacology Authors: Olatz Ibarra Barrueta Estela Garc ía Martín Piedad L ópez Sánchez Esther Ram írez Herráiz Vicente Merino Boh órquez Arantza Ais Larisgoitia Source Type: research
[TRANSLATED ARTICLE] Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases
CONCLUSIONS: In this context of chronic treatments with teratogenic potential, it is necessary to highlight the importance of pregnancy planning to select the safest drug. Given the quality of the available data, it is still necessary to continuously update the information, as well as to promote observational studies of cohorts of pregnant patients and men of childbearing age, including prospective studies, in order to generate more scientific evidence.PMID:36732114 | DOI:10.1016/j.farma.2022.12.016 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - February 2, 2023 Category: Drugs & Pharmacology Authors: Olatz Ibarra Barrueta Estela Garc ía Martín Piedad L ópez Sánchez Esther Ram írez Herráiz Vicente Merino Boh órquez Arantza Ais Larisgoitia Source Type: research
[TRANSLATED ARTICLE] Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases
CONCLUSIONS: In this context of chronic treatments with teratogenic potential, it is necessary to highlight the importance of pregnancy planning to select the safest drug. Given the quality of the available data, it is still necessary to continuously update the information, as well as to promote observational studies of cohorts of pregnant patients and men of childbearing age, including prospective studies, in order to generate more scientific evidence.PMID:36732114 | DOI:10.1016/j.farma.2022.12.016 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - February 2, 2023 Category: Drugs & Pharmacology Authors: Olatz Ibarra Barrueta Estela Garc ía Martín Piedad L ópez Sánchez Esther Ram írez Herráiz Vicente Merino Boh órquez Arantza Ais Larisgoitia Source Type: research
Immunogenetic Determinants of Relapse and Non-Relapse Mortality Following Haploidentical HCT with Ptcy and T Cell Costimulation Blockade with Abatacept
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2023 Category: Hematology Authors: Sarita Rani Jaiswal, Ashraf Saifullah, Jaganath Arunachalam, Rohit Lakhchaura, Mahak Agarwal, Prakash Baligar, Subhrajit Biswas, Suparno Chakrabarti Tags: POSTER SESSION: RELAPSE - CLINICAL: PREVENTION AND TREATMENT Source Type: research
